SG11201407688QA - Laquinimod formulations without alkalizing agent - Google Patents

Laquinimod formulations without alkalizing agent

Info

Publication number
SG11201407688QA
SG11201407688QA SG11201407688QA SG11201407688QA SG11201407688QA SG 11201407688Q A SG11201407688Q A SG 11201407688QA SG 11201407688Q A SG11201407688Q A SG 11201407688QA SG 11201407688Q A SG11201407688Q A SG 11201407688QA SG 11201407688Q A SG11201407688Q A SG 11201407688QA
Authority
SG
Singapore
Prior art keywords
international
pharmaceutical composition
subject
stable pharmaceutical
subject invention
Prior art date
Application number
SG11201407688QA
Other languages
English (en)
Inventor
Gadi Sarfati
Ioana Lovinger
Danit Licht
Muhammad Safadi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SG11201407688QA publication Critical patent/SG11201407688QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201407688QA 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent SG11201407688QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261670268P 2012-07-11 2012-07-11
PCT/US2013/049894 WO2014011750A1 (en) 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent

Publications (1)

Publication Number Publication Date
SG11201407688QA true SG11201407688QA (en) 2014-12-30

Family

ID=49914501

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407688QA SG11201407688QA (en) 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent
SG10201700198VA SG10201700198VA (en) 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201700198VA SG10201700198VA (en) 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent

Country Status (19)

Country Link
US (1) US20140018386A1 (enrdf_load_stackoverflow)
EP (1) EP2872141A4 (enrdf_load_stackoverflow)
JP (1) JP2015527321A (enrdf_load_stackoverflow)
KR (1) KR20150036553A (enrdf_load_stackoverflow)
CN (1) CN104470519A (enrdf_load_stackoverflow)
AR (1) AR091706A1 (enrdf_load_stackoverflow)
AU (1) AU2013290274A1 (enrdf_load_stackoverflow)
BR (1) BR112015000321A2 (enrdf_load_stackoverflow)
CA (1) CA2873230A1 (enrdf_load_stackoverflow)
EA (1) EA201590193A1 (enrdf_load_stackoverflow)
HK (1) HK1209054A1 (enrdf_load_stackoverflow)
IL (1) IL236229A0 (enrdf_load_stackoverflow)
MX (1) MX2015000398A (enrdf_load_stackoverflow)
NZ (1) NZ630241A (enrdf_load_stackoverflow)
SG (2) SG11201407688QA (enrdf_load_stackoverflow)
TW (1) TW201408299A (enrdf_load_stackoverflow)
UA (1) UA115555C2 (enrdf_load_stackoverflow)
WO (1) WO2014011750A1 (enrdf_load_stackoverflow)
ZA (1) ZA201500287B (enrdf_load_stackoverflow)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2234485E (pt) 2007-12-20 2014-02-17 Teva Pharma Preparações de laquinimod estáveis
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
BR112015010193A2 (pt) 2012-11-07 2017-07-11 Teva Pharma sais de amina de laquinimod
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
MX2016013944A (es) 2014-04-29 2017-01-09 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad.
CN107823150A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种可快速分散的片剂及其制备方法
CN107823168A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种快速溶解的片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
NZ592897A (en) * 2005-10-19 2012-12-21 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
EA018031B1 (ru) * 2006-06-12 2013-05-30 Тева Фармасьютикал Индастриз, Лтд. Стабильные препараты лаквинимода
PT2234485E (pt) * 2007-12-20 2014-02-17 Teva Pharma Preparações de laquinimod estáveis
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
BR112014002092A2 (pt) * 2011-07-28 2017-02-21 Teva Pharma tratamento de esclerose múltipla com combinação de laquinimod e interferon-beta

Also Published As

Publication number Publication date
EA201590193A1 (ru) 2015-04-30
UA115555C2 (uk) 2017-11-27
EP2872141A4 (en) 2016-01-13
EP2872141A1 (en) 2015-05-20
BR112015000321A2 (pt) 2017-06-27
CA2873230A1 (en) 2014-01-16
HK1209054A1 (zh) 2016-03-24
ZA201500287B (en) 2016-10-26
KR20150036553A (ko) 2015-04-07
WO2014011750A1 (en) 2014-01-16
AU2013290274A1 (en) 2014-11-27
US20140018386A1 (en) 2014-01-16
WO2014011750A8 (en) 2014-12-04
TW201408299A (zh) 2014-03-01
NZ630241A (en) 2017-09-29
JP2015527321A (ja) 2015-09-17
CN104470519A (zh) 2015-03-25
MX2015000398A (es) 2015-04-10
AR091706A1 (es) 2015-02-25
SG10201700198VA (en) 2017-02-27
IL236229A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
SG11201407688QA (en) Laquinimod formulations without alkalizing agent
SG11201408174UA (en) Antibody formulation
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201903514VA (en) Novel cd47 monoclonal antibodies and uses thereof
SG11201906412SA (en) Pyridine compounds as allosteric shp2 inhibitors
SG11201408173WA (en) Pyrimidinyl tyrosine kinase inhibitors
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201808693WA (en) Anti-il-33 antibodies, compositions, methods and uses thereof
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201811580SA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201406973PA (en) Complement pathway modulators and uses thereof
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201406987UA (en) Glucokinase activator compositions for the treatment of diabetes
SG11201408511QA (en) Liquid preparations of amines and organic acids stabilized by salts
SG11201408509PA (en) Racecadotril lipid compositions
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201903417PA (en) Ringing gel composition
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers